| Autor: |
Taenaka H; Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, California, United States.; Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, California, United States.; Department of Anesthesiology and Intensive Care Medicine, Osaka University Graduate School of Medicine, Suita, Japan., Fang X; Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, California, United States.; Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, California, United States., Maishan M; Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, California, United States.; Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, California, United States., Trivedi A; Department of Laboratory Medicine, University of California, San Francisco, California, United States., Wick KD; Division of Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States., Gotts JE; Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, California, United States.; Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, California, United States., Martin TR; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, United States., Calfee CS; Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, California, United States.; Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, California, United States., Matthay MA; Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, California, United States.; Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, California, United States. |
| Abstrakt: |
Neutrophils are the first leukocytes to be recruited to sites of inflammation in response to chemotactic factors released by activated macrophages and pulmonary epithelial and endothelial cells in bacterial pneumonia, a common cause of acute respiratory distress syndrome (ARDS). Although neutrophilic inflammation facilitates the elimination of pathogens, neutrophils also may cause bystander tissue injury. Even though the presence of neutrophils in alveolar spaces is a key feature of acute lung injury and ARDS especially from pneumonia, their contribution to the pathogenesis of lung injury is uncertain. The goal of this study was to elucidate the role of neutrophils in a clinically relevant model of bacterial pneumonia. We investigated the effect of reducing neutrophils in a mouse model of pneumococcal pneumonia treated with antibiotics. Neutrophils were reduced with anti-lymphocyte antigen 6 complex locus G6D (Ly6G) monoclonal antibody 24 h before and immediately preceding infection. Mice were inoculated intranasally with Streptococcus pneumoniae and received ceftriaxone 12 h after bacterial inoculation. Neutrophil reduction in mice treated with ceftriaxone attenuated hypoxemia, alveolar permeability, epithelial injury, pulmonary edema, and inflammatory biomarker release induced by bacterial pneumonia, even though bacterial loads in the distal air spaces of the lung were modestly increased as compared with antibiotic treatment alone. Thus, when appropriate antibiotics are administered, lung injury in the early phase of bacterial pneumonia is mediated in part by neutrophils. In the early phase of bacterial pneumonia, neutrophils contribute to the severity of lung injury, although they also participate in host defense. NEW & NOTEWORTHY Neutrophil accumulation is a key feature of ARDS, but their contribution to the pathogenesis is still uncertain. We investigated the effect of reducing neutrophils in a clinically relevant mouse model of pneumococcal pneumonia treated with antibiotics. When appropriate antibiotics were administered, neutrophil reduction with Ly6G antibody markedly attenuated lung injury and improved oxygenation. In the early phase of bacterial pneumonia, neutrophils contribute to the severity of lung injury, although they also participate in host defense. |
